argenx’s VYVGART Shows Clinically Meaningful Benefit in Phase 3 Myositis Study, Stock Jumps

argenx’s efgartigimod met primary endpoint in Phase 3 ALKIVIA trial for autoimmune myositis, showing 15.4-point TIS improvement at Week 52.